10x Genomics affiliate plans $453K stock sale

10x Genomics, Inc. (TXG) received a Rule 144 notice covering a proposed sale of 5,723 shares of its Class A common stock for the account of affiliate Shehnaaz Suliman through J.P.

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) received a Rule 144 notice covering a proposed sale of 5,723 shares of its Class A common stock for the account of affiliate Shehnaaz Suliman through J.P. Morgan Securities LLC on Nasdaq. The shares were acquired via RSU awards vesting between August 21, 2024 and May 21, 2025.

Key Figures

Shares to be sold under Rule 144: 5,723 shares Approximate aggregate market value: $452,689.20 Shares sold during past 3 months: 5,723 shares +3 more

6 metrics

Shares to be sold under Rule 144 5,723 shares Class A common stock of 10x Genomics, Inc. proposed for sale

Approximate aggregate market value $452,689.20 Value associated with 5,723 Class A shares to be sold

Shares sold during past 3 months 5,723 shares Class A common stock sale reported for August 24, 2026

Aggregate proceeds from recent sale $140,477.91 Proceeds for 5,723 shares sold on August 24, 2026

RSU vesting period for acquired shares August 21, 2024 to May 21, 2025 Period during which RSU awards that yielded these shares vested

Date of Rule 144 notice September 22, 2026 Date the notice related to the proposed sale was signed

Key Terms

Rule 144, RSU Vesting, Class A Common, affiliate, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU Vesting financial

"Class A Common | 08/21/2024 | RSU Vesting | Issuer"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

Class A Common financial

"Class A Common | JP Morgan Securities LLC"

affiliate regulatory

"Affiliate 144: Securities Information"

attorney-in-fact regulatory

"as agent and attorney-in-fact for Shehnaaz Suliman"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for TXG disclose?

It discloses a proposed Rule 144 sale of 5,723 shares of 10x Genomics, Inc. Class A common stock for the account of affiliate Shehnaaz Suliman through J.P. Morgan Securities LLC on Nasdaq.

How many TXG shares are covered by this Rule 144 notice?

The notice covers a proposed sale of 5,723 shares of 10x Genomics, Inc. Class A common stock. This figure appears both as the amount of securities to be sold and as securities sold during the past three months.

How were the TXG shares in this Form 144 acquired?

The filing states that the shares were acquired via an RSU award with vesting between August 21, 2024 and May 21, 2025, identified in the form as “RSU Vesting” and “Compensation.”

What approximate market value is associated with the TXG shares to be sold?

The securities information section lists an approximate aggregate market value of $452,689.20 for the 5,723 shares of Class A common stock covered by this proposed Rule 144 sale.

What past TXG share sales by this affiliate are disclosed?

The filing lists a sale by Shehnaaz Suliman of 5,723 shares of Class A common stock on August 24, 2026, with aggregate proceeds of $140,477.91 in the “Securities Sold During The Past 3 Months” section.

Who is acting as broker for the proposed TXG share sale?

The broker listed is J.P. Morgan Securities LLC, located at 270 Park Avenue, 10th Floor, New York, NY 10017, which also signed the notice as agent and attorney-in-fact for Shehnaaz Suliman.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 06:28 PM Accepted by SEC EDGAR 09/22/2026 - 06:27 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001713070
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	10X Genomics, Inc.
SEC File Number	001-39035
Address of Issuer	6230 Stoneridge Mall Road Pleasanton CALIFORNIA 94588
Phone	925-401-7300
Name of Person for Whose Account the Securities are To Be Sold	Shehnaaz Suliman
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	JP Morgan Securities LLC 270 Park Avenue, 10th Floor New York NY 10017	5723	452689.2	120212296	09/22/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	08/21/2024	RSU Vesting	Issuer			5723	08/21/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shehnaaz Suliman Care of TXG Genomics Inc 6230 Stoneridge Mall Road Pleasanton CA 94588	Class A Common	08/24/2026	5723	140477.91

144: Remarks and Signature

Remarks	The shares represented on this filing were acquired via RSU award between 08/21/24 and 05/21/25.
Date of Notice	09/22/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Shehnaaz Suliman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)